ImmunoCellular Therapeutics, Ltd. (IMUC)
USD 0.15
(53.85%)
USD 0.15
(53.85%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 6.1 Million USD | 23.09% |
| 2022 | 4.95 Million USD | 169.74% |
| 2021 | 1.83 Million USD | 1240.22% |
| 2020 | 137.12 Thousand USD | 0.0% |
| 2017 | 2.36 Million USD | -78.06% |
| 2016 | 10.75 Million USD | 28.66% |
| 2015 | 8.36 Million USD | 343.16% |
| 2014 | 1.88 Million USD | -23.52% |
| 2013 | 2.46 Million USD | -37.56% |
| 2012 | 3.95 Million USD | 0.83% |
| 2011 | 3.91 Million USD | 29.36% |
| 2010 | 3.02 Million USD | 706.27% |
| 2009 | 375.72 Thousand USD | 99.8% |
| 2008 | 188.04 Thousand USD | 158.46% |
| 2007 | 72.75 Thousand USD | -91.73% |
| 2006 | 880.17 Thousand USD | -36.17% |
| 2005 | 1.37 Million USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | - USD | -100.0% |
| 2023 Q2 | - USD | 0.0% |
| 2023 FY | 6.1 Million USD | 23.09% |
| 2022 FY | 4.95 Million USD | 169.74% |
| 2022 Q4 | 4.95 Million USD | 11.61% |
| 2022 Q3 | 4.44 Million USD | 0.0% |
| 2022 Q1 | 3.5 Million USD | 6.75% |
| 2021 FY | 1.83 Million USD | 1240.22% |
| 2021 Q3 | 2.08 Million USD | 0.0% |
| 2021 Q1 | - USD | -100.0% |
| 2021 Q4 | 3.28 Million USD | 57.13% |
| 2020 Q4 | 137.12 Thousand USD | 0.0% |
| 2020 FY | 137.12 Thousand USD | 0.0% |
| 2018 Q2 | 401.94 Thousand USD | -73.08% |
| 2018 Q1 | 1.49 Million USD | -36.75% |
| 2017 Q2 | 7.74 Million USD | -22.74% |
| 2017 Q4 | 2.36 Million USD | -67.66% |
| 2017 FY | 2.36 Million USD | -78.06% |
| 2017 Q3 | 7.29 Million USD | -5.79% |
| 2017 Q1 | 10.02 Million USD | -6.79% |
| 2016 Q4 | 10.75 Million USD | 1.52% |
| 2016 Q3 | 10.59 Million USD | 43.48% |
| 2016 Q1 | 8.16 Million USD | -2.38% |
| 2016 Q2 | 7.38 Million USD | -9.52% |
| 2016 FY | 10.75 Million USD | 28.66% |
| 2015 Q2 | 3.71 Million USD | -19.36% |
| 2015 FY | 8.36 Million USD | 343.16% |
| 2015 Q4 | 8.36 Million USD | 83.35% |
| 2015 Q1 | 4.6 Million USD | 144.23% |
| 2015 Q3 | 4.56 Million USD | 22.72% |
| 2014 Q4 | 1.88 Million USD | -2.85% |
| 2014 Q3 | 1.94 Million USD | -18.34% |
| 2014 Q2 | 2.37 Million USD | -14.68% |
| 2014 Q1 | 2.78 Million USD | 12.99% |
| 2014 FY | 1.88 Million USD | -23.52% |
| 2013 Q2 | 3.13 Million USD | -52.81% |
| 2013 FY | 2.46 Million USD | -37.56% |
| 2013 Q4 | 2.46 Million USD | -48.15% |
| 2013 Q3 | 4.75 Million USD | 51.79% |
| 2013 Q1 | 6.64 Million USD | 68.11% |
| 2012 Q3 | 7.66 Million USD | -21.12% |
| 2012 Q1 | 7.86 Million USD | 100.74% |
| 2012 Q2 | 9.72 Million USD | 23.57% |
| 2012 FY | 3.95 Million USD | 0.83% |
| 2012 Q4 | 3.95 Million USD | -48.47% |
| 2011 FY | 3.91 Million USD | 29.36% |
| 2011 Q1 | 6.52 Million USD | 115.23% |
| 2011 Q2 | 6.37 Million USD | -2.18% |
| 2011 Q3 | 4.39 Million USD | -31.08% |
| 2011 Q4 | 3.91 Million USD | -10.85% |
| 2010 Q1 | 873.39 Thousand USD | 132.46% |
| 2010 Q3 | 2.71 Million USD | -16.09% |
| 2010 Q2 | 3.23 Million USD | 270.94% |
| 2010 Q4 | 3.02 Million USD | 11.44% |
| 2010 FY | 3.02 Million USD | 706.27% |
| 2009 Q1 | 220.33 Thousand USD | 17.17% |
| 2009 Q3 | 205.14 Thousand USD | -41.5% |
| 2009 FY | 375.72 Thousand USD | 99.8% |
| 2009 Q4 | 375.72 Thousand USD | 83.15% |
| 2009 Q2 | 350.66 Thousand USD | 59.15% |
| 2008 Q2 | 100.21 Thousand USD | 7.87% |
| 2008 FY | 188.04 Thousand USD | 158.46% |
| 2008 Q4 | 188.04 Thousand USD | 142.98% |
| 2008 Q1 | 92.89 Thousand USD | 27.69% |
| 2008 Q3 | 77.39 Thousand USD | -22.77% |
| 2007 FY | 72.75 Thousand USD | -91.73% |
| 2007 Q4 | 72.75 Thousand USD | -51.13% |
| 2007 Q3 | 148.86 Thousand USD | 28.49% |
| 2007 Q1 | 3.89 Million USD | 342.21% |
| 2007 Q2 | 115.86 Thousand USD | -97.02% |
| 2006 Q2 | 1.39 Million USD | -5.44% |
| 2006 FY | 880.17 Thousand USD | -36.17% |
| 2006 Q4 | 880.17 Thousand USD | -37.33% |
| 2006 Q3 | 1.4 Million USD | 0.47% |
| 2006 Q1 | 1.47 Million USD | 0.0% |
| 2005 FY | 1.37 Million USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -22142.937% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 35.538% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 91.58% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -654.445% |
| Rebus Holdings, Inc. | 5.24 Million USD | -16.404% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 89.66% |
| Qrons Inc. | 1.48 Million USD | -309.878% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -397.622% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 91.855% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -13552.016% |
| Skye Bioscience, Inc. | 14.07 Million USD | 56.639% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 88.553% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 36.319% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -1347.431% |
| SQZ Biotechnologies Company | 50.03 Million USD | 87.806% |
| Intellipharmaceutics International Inc. | 12 Million USD | 49.188% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -58.432% |
| Mesoblast Limited | 188.44 Million USD | 96.762% |
| Marizyme, Inc. | 26.67 Million USD | 77.126% |
| Genus plc | 485 Million USD | 98.742% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -4.438% |
| Pharming Group N.V. | 244.07 Million USD | 97.5% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -203.558% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -142.492% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -60.576% |
| ContraFect Corporation | 32.53 Million USD | 81.243% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -207.974% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -59.417% |
| IMV Inc. | 37.93 Million USD | 83.914% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 48.193% |
| MultiCell Technologies, Inc. | 1617.67 USD | -377103.323% |
| ONE Bio Corp. | 27.49 Million USD | 77.808% |
| Accustem Sciences Inc. | 1.07 Million USD | -465.39% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 92.118% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -188.497% |
| Q BioMed Inc. | 8.13 Million USD | 24.973% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 92.643% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -18.575% |
| Biomind Labs Inc. | 1.49 Million USD | -307.17% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 94.86% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 32.517% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 66.844% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -325.558% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -4194.243% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -2934.023% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -6.197% |
| GB Sciences, Inc. | 5.41 Million USD | -12.632% |
| Alpha Cognition Inc. | 7.16 Million USD | 14.835% |
| HST Global, Inc. | 593.59 Thousand USD | -927.961% |
| CSL Limited | 18.62 Billion USD | 99.967% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -384.589% |
| Halberd Corporation | 728.71 Thousand USD | -737.347% |
| Enzolytics Inc. | 365.26 Million USD | 98.329% |
| Agentix Corp. | 2.51 Million USD | -143.05% |
| Resverlogix Corp. | 67.39 Million USD | 90.946% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -627.515% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 98.629% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -256.004% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 75.342% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 48.737% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -66.484% |
| AVAX Technologies, Inc. | 3.99 Million USD | -52.787% |
| Zenith Capital Corp. | 27.56 Thousand USD | -22033.211% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.54% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -2456.8% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -63.401% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -796.24% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -125.026% |
| Kadimastem Ltd | 3.5 Million USD | -74.098% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -9016.982% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 87.86% |
| BioStem Technologies, Inc. | 15.9 Million USD | 61.635% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -1213.088% |
| LadRx Corporation | 2.2 Million USD | -177.293% |
| Cell Source, Inc. | 15.8 Million USD | 61.397% |
| Regen BioPharma, Inc. | 5.45 Million USD | -11.805% |
| Regen BioPharma, Inc. | 5.45 Million USD | -11.805% |
| NovAccess Global Inc. | 7.86 Million USD | 22.375% |
| Affymax, Inc. | 8.87 Million USD | 31.215% |
| Itoco Inc. | 1.65 Million USD | -269.108% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -197.427% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -0.875% |
| Mobile Lads Corp. | 1.31 Million USD | -364.554% |
| CytoDyn Inc. | 127.89 Million USD | 95.229% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -14498.208% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -289.555% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 44.756% |
| SYBLEU INC | 681.41 Thousand USD | -795.478% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| International Stem Cell Corporation | 5.27 Million USD | -15.632% |
| Bioxytran, Inc. | 3.24 Million USD | -87.78% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -875.043% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -32.158% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 85.116% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 72.594% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -201.271% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -11.389% |
| Neutra Corp. | 973.52 Thousand USD | -526.782% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 78.97% |
| PureTech Health plc | 125.58 Million USD | 95.141% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -62.409% |
| IXICO plc | 1.9 Million USD | -221.104% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 70.277% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 94.094% |
| CSL Limited | 18.62 Billion USD | 99.967% |
| Cellectis S.A. | 249.36 Million USD | 97.553% |